Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7,005.00
Bid: 7,021.00
Ask: 7,022.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.01%)
Open: 6,927.00
High: 7,023.00
Low: 6,849.00
Yest. Close: 6,858.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Britain's Immunocore raises $320 mln in record financing round

By Padraic Halpin DUBLIN, July 16 (Reuters) - Britain's Immunocore completed Europe's largest ever financing round by a private life sciences company on Thursday, raising $320 million from investors including Eli Lilly & Co, Malin and Woodford Investment Management. The Oxford-based b

16 Jul 15 06:11

UPDATE 3-Greece bans export of 25 drugs after pharmacists' supply warnings

(Adds AstraZeneca comment) By Lefteris Karagiannopoulos ATHENS, July 14 (Reuters) - Greece has decided to ban the export of 25 types of drugs, the Health Ministry said on Tuesday, following warnings of possible shortages that risked leading to a humanitarian crisis. A ministry s

14 Jul 15 17:14

UPDATE 2-Greece bans export of 25 drugs after pharmacists' supply warnings

(Adds pharmaceutical warehouses' complaint, Novartis response) By Lefteris Karagiannopoulos ATHENS, July 14 (Reuters) - Greece has decided to ban the export of 25 types of drugs, the Health Ministry said on Tuesday, following warnings of possible shortages that risked leading to a hum

14 Jul 15 15:59

FTSE 100 movers: Meggitt surges on merger mumbles, Carney chat hits housebuilders

(ShareCast News) - London markets edged lower on Tuesday, as losses from housebuilders, engineers and financials eclipsed gains made by industrial metals. As of 14:00 BST, the FTSE 100 was trading 0.2% lower at 6,727. Shares in defence and aerospace engineer Meggitt rose following a report in the F

14 Jul 15 14:29

London midday: Homebuilders knocked lower by remarks from Carney

(ShareCast News) - Bank of England Governor Mark Carney told the Treasury Select Committee Bank Rate may be headed higher a little bit sooner than markets anticipated, sending stocks - especially homebuilders - listed on the second tier index promptly lower. As of 12:13 the top flight index was off

14 Jul 15 13:09

TOP NEWS SUMMARY: UK Inflation Slips Back To Zero In June

14 Jul 15 10:22

LONDON BRIEFING: Iran Nuclear Agreement Hits Oil Prices

14 Jul 15 07:25

FDA Approves AstraZeneca's Iressa As Lung Cancer Treatment

14 Jul 15 05:24

UPDATE 1-AstraZeneca lung cancer drug approved as first-line treatment

(Adds details) July 13 (Reuters) - The U.S. Food and Drug Administration approved AstraZeneca Plc's drug, Iressa, as a first-line treatment for a common form of lung cancer. The FDA said on Tuesday the approval was based on results from a trial of 106 patients with previously untreate

13 Jul 15 18:37

FDA approves AstraZeneca's lung cancer drug as first-line treatment

July 13 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca Plc's drug, Iressa, as a first-line treatment for a common form of lung cancer. The drug was previously approved for use in non-small cell lung cancer patients only after they did not respond to chemotherapy.

13 Jul 15 17:54

Monday broker round-up

(ShareCast News) - ARM Holdings: JP Morgan downgrades to underweight and lowers target to 900p from 950p; Exane reiterates outperform with 1,400p target. AstraZeneca: Goldman Sachs stays at neutral and Jefferies at buy. British American Tobacco: Nomura starts coverage at buy with 3,920p target. Bu

13 Jul 15 12:05

BROKER RATINGS SUMMARY: UBS Upgrades IAG To Buy From Neutral

13 Jul 15 08:32

TOP NEWS SUMMARY: Chinese Stocks Rebound On Flurry Of Support Measures

9 Jul 15 10:27

Astrazeneca offloads Crohn's treatment for $215m

Astrazeneca has sold global rights outside the US for its Entocort medicine, which treats Crohn's disease and ulcerative colitis, to Japan's Zeria Group for $215m Entocort generated product sales of $53m outside the US in 2014 for the FTSE 100 drug group, which said the disposal to Zeria subsidiary

9 Jul 15 09:01

LONDON BRIEFING: Shares Firm On Chinese Stock Rebound And Dovish Fed

9 Jul 15 07:32

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.